BioSpace News Archive

The National Comprehensive Cancer Network® Oncology Research Program announced grants awarded to foster and enhance quality-of-care, guideline concordance, and innovations in care delivery for patients with limited-stage and extensive-stage small cell lung cancer.

Etiometry, the leader in clinical decision-support software, shares exciting new study results from ten hospitals, including Boston Children’s Hospital, Children’s of Alabama, Children’s National Hospital and St. Louis Children’s Hospital, that demonstrate the significant impact its platform has on outcomes for critically ill patients.

The Lupus Foundation of America and Lupus Canada are pleased to announce Joan Wither, MD, PhD, FRCPC has been awarded the 2023 Lupus Canada Catalyst Award for her study “Interferon and Prediction of Treatment Responses in Lupus Nephritis,” focused on interferon -induced genes to predict treatment response in lupus nephritis with a new technique that could be incorporated into routine analysis of kidney biopsies.

Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest” or the “Company”) announces that, further to its news release of August 3, 2023, a Notice of Requisition for General Meeting delivered by Garth Greenham and LMC Communications Inc. dated July 24, 2023

APRINOIA Therapeutics, a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, and certain rare dementia and movement disorders, announced that its Board of Directors has appointed Mark S. Shearman, Ph.D. as Chief Executive Officer.

All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -

Nexus Pharmaceuticals LLC announced that the U.S. Food and Drug Administration (FDA) issued a notice in the Federal Register that ephedrine sulfate should not be bulked by compounding facilities.

Soterix Medical Inc. announces the launch of a Phase-2 clinical trial that will evaluate the combination of REMOTE-tDCS and a brain training program for the treatment of long COVID.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.